Paradoxical inhibition of fibrinogen binding and potentiation of α-granule release by specific types of inhibitors of glycoprotein IIb-IIIa

Cardiovascular Research

Volumn 45, Issue 2, 2000, Pages 437-446

  Schneider, David J ^a   Taatjes, Douglas J ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Atherosclerosis; Blood flow; Platelets; Receptors; Thrombosis embolism

Indexed keywords

ABCIXIMAB; CD63 ANTIGEN; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; ORBOFIBAN; PADGEM PROTEIN;

ARTICLE; ATHEROSCLEROSIS; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ALANINE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICROSCOPY, CONFOCAL; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; PROTEIN BINDING; PYRROLIDINES;

EID: 0033956763     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00253-9     Document Type: Article

References (23)

1. Bennet J.S., Vilare G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 64:1979;1393-1398.
2. Marguerie G.A., Edgington T.S., Plow E.F. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem. 255:1980;154-160.
3. Coller B.S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 76:1985;101-108.
4. Schneider D.J., Taatjes D.J., Sobel B.E. Increased reactivity of platelets induced by fibrinogen independent of Its binding to the IIb-IIIa surface glycoprotein: A potential contributor to cardiovascular risk. J Am Coll Cardiol. 33:1999;261-266.
5. Fuster V., Stein B., Ambrose J.A., et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation. 82:(suppl 3):1990;II47-II59.
6. Califf R.M., Lincoff A.M., Tcheng J.E., Topol E.J. An overview of the results of the EPIC trial. Eur Heart J. 16:(Suppl. L):1995;43-49.
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous revascularization. New Engl J Med. 336:1997;1689-1696.
8. Tcheng J.E., Harrington R.A., Kottke-Marchant K., et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation. 91:1995;2151-2157.
9. Kereiakes D.J., Kleiman N.S., Ambrose J., et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542.
10. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 349:1997;1429-1435.
11. Schulman S.P., Goldschmidt-Clermont P.J., Topol E.J., et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation. 94:1996;2083-2089.
12. The platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) trial investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 1998;338:1488-1497.
13. Ohman E.M., Kleiman N.S., Gacioch G., et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa receptor blockade with integrilin in acute myocardial infarction. Circulation. 95:1997;846-854.
14. Antman E.M., Giugliano R.P., McCabe C.H., et al. Abciximab (ReoPro) potentiates thrombolysis in ST-elevation myocardial infarction: Results of TIMI 14 trial. J Am Coll Cardiol. 31(Suppl A):1998;191A.
15. Schneider D.J., Tracy P.B., Mann K.G., Sobel B.E. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation. 96:1997;2877-2883.
16. Rand M.D., Lock J.B., Veer C.V., Gaffney D.P., Mann K.G. Blood clotting in minimally altered whole blood. Blood. 88:1996;3432-3445.
17. Xia V., Wong T., Liu Q., et al. Optimally functional fluorescein isothiocyanate-labeled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol. 93:1996;204-214.
18. Holmes M.B., Sobel B.E., Schneider D.J. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol. 84:1999;203-207.
19. Coller B.S. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation. 97:1998;5-9.
20. Vorchheimer D.A., Fuster V. Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety. Circulation. 97:1998;312-314.
21. Mickelson J.K., Ali M.N., Kleiman N.S., et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol. 33:1999;97-106.
22. Peter K., Schwarz M., Ylanne J., et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood. 92:1998;3240-3249.
23. Frelinger A.L., Cohen I., Plow E.F., et al. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 265:1990;6346-6352.